Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ARTV

Artiva Biotherapeutics Inc

Mar 20 • 09:39AM ET

4.40

Dollar change -0.04
Percentage change -0.90	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD REGN BMY AMGN MRNA PFE NVAX VRTX SAGE NTLA

| Held by: VTI IWM VXF IBB IWO IWN VTWO IWC RSSL VTWG

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-	Insider Own	50.78%	Shs Outstand	24.29M	Perf Week	-21.43%
Market Cap	106.87M	Forward P/E	-	EPS next Y	-3.58	Insider Trans	0.00%	Shs Float	11.95M	Perf Month	9.45%
Income	-	PEG	-	EPS next Q	-0.73	Inst Own	63.35%	Short Float	9.41%	Perf Quarter	-57.69%
Sales	-	P/S	-	EPS this Y	47.67%	Inst Trans	9.15%	Short Ratio	12.90	Perf Half Y	-59.82%
Book/sh	8.28	P/B	0.53	EPS next Y	-11.86%	ROA	-	Short Interest	1.12M	Perf Year	-
Cash/sh	6.04	P/C	0.73	EPS next 5Y	12.20%	ROE	-	52W Range	3.37 - 17.31	Perf YTD	-56.35%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-63.82%	ROI	-	52W High	-74.58%	Beta	-
Dividend TTM	-	Quick Ratio	11.33	Sales past 5Y	181.38%	Gross Margin	-	52W Low	30.56%	ATR (14)	0.63
Dividend Ex-Date	-	Current Ratio	11.33	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	43.46	Volatility	19.11% 13.06%
Employees	77	Debt/Eq	0.07	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	21.50
Option/Short	No / Yes	LT Debt/Eq	0.06	EPS Q/Q	24.33%	Payout	-	Rel Volume	0.72	Prev Close	4.44
Sales Surprise	-100.00%	EPS Surprise	-1.99%	Sales Q/Q	-100.00%	Earnings	Feb 26	Avg Volume	87.19K	Price	4.40
SMA20	-6.61%	SMA50	-17.77%	SMA200	-55.43%	Trades		Volume	4,530	Change	-0.90%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-30-24	Initiated	H.C. Wainwright	Buy	$20
Aug-13-24	Initiated	Wedbush	Outperform	$18
Aug-13-24	Initiated	TD Cowen	Buy
Aug-13-24	Initiated	Needham	Buy	$23
Aug-13-24	Initiated	Jefferies	Buy	$21
Aug-13-24	Initiated	Cantor Fitzgerald	Overweight	$23

Feb-20-25 04:05PM	Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference (GlobeNewswire) -5.72%
Jan-29-25 04:05PM	Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D. (GlobeNewswire)
Nov-12-24 04:05PM	Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) -10.48%
Nov-11-24 04:05PM	Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-22-24 04:05PM	Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors (GlobeNewswire) +7.82%
04:05PM	Loading…
Sep-10-24 04:05PM	Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Aug-29-24 04:05PM	Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-18-24 07:08PM	Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering (GlobeNewswire)

Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RA CAPITAL MANAGEMENT, L.P.	Director	Jul 22 '24	Buy	12.00	8,333,333	99,999,996	8,693,579	Jul 24 04:27 PM
5AM Partners VI, LLC	10% Owner	Jul 22 '24	Buy	12.00	833,333	9,999,996	1,182,054	Jul 24 04:15 PM
venBio Global Strategic Fund I	10% Owner	Jul 22 '24	Buy	12.00	416,666	4,999,992	1,936,637	Jul 22 08:26 PM
GC Corp.	10% Owner	Jul 22 '24	Buy	12.00	1,666,666	19,999,992	3,306,900	Jul 22 08:25 PM
GC Corp.	10% Owner	Jul 22 '24	Buy	12.00	416,666	4,999,992	1,260,512	Jul 22 08:25 PM
Huh Yong-Jun	Director	Jul 22 '24	Buy	12.00	2,083,332	24,999,984	3,306,900	Jul 22 08:22 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARTV

Artiva Biotherapeutics Inc

Upgrade your FINVIZ experience